COVID-19 in multiple sclerosis patients treated with dimethyl fumarate

J Neurol. 2021 Sep;268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. Epub 2021 Feb 20.

Authors

Fioravante Capone¹, Elisabetta Ferraro², Francesco Motolese³, Vincenzo Di Lazzaro³

Affiliations

¹ Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Institute of Neurology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy. f.capone@unicampus.it.
² San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
³ Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Institute of Neurology, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Dimethyl Fumarate / therapeutic use
Fingolimod Hydrochloride
Humans
Immunosuppressive Agents / adverse effects
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting* / drug therapy
SARS-CoV-2

Substances

Immunosuppressive Agents
Dimethyl Fumarate
Fingolimod Hydrochloride